Literature DB >> 4045723

Cardiovascular effects of doxorubicin-induced toxicity in the intact Lou/M Wsl rat and in isolated heart preparations.

D J de Wildt, Y de Jong, F C Hillen, P A Steerenberg, Q G van Hoesel.   

Abstract

Hemodynamic effects were followed for 25 days in conscious nontumor bearing Lou/M Wsl rats during i.v. administration of doxorubicin (DXR) (1 mg/kg) on 5 consecutive days and then weekly. At day 24 cardiac output was significantly reduced in the DXR-treated group (cumulative dose of 7 mg/kg) in comparison with a saline-treated group, suggesting a reduction in myocardial performance. Urethane anesthesia at day 25 depressed cardiac output in control rats whereas this variable was not influenced in DXR-treated rats. Furthermore, blood pressure was significantly higher within DXR-treated rats, suggesting the presence of compensatory mechanisms. Separate experiments 25 days after the first DXR administration (cumulative dose of 7 mg/kg) demonstrated that the inotropic response toward dobutamine or norepinephrine as well as the vasoconstrictor response toward norepinephrine were impaired profoundly, suggesting compensatory mechanisms were functioning within the DXR-treated rats around day 25. In the isolated and perfused rat heart no changes in myocardial contraction under either basal or inotropic stimulatory conditions were observed 24 days after DXR treatment, indicating extracardiac phenomena have to contribute to a reduction in cardiac output and the occurrence of counter regulation mechanisms as observed in the in vivo experiments. However, after a cumulative dose of 11 mg/kg (at day 52), contraction function appeared to be disturbed upon contractility demand by dobutamine in the isolated heart. This observation supports the histological evidence of cardiomyopathy occurring at that time.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4045723

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Significance of adaptation mechanisms in adriamycin induced congestive heart failure.

Authors:  P K Singal; N Siveski-Iliskovic; N Kaul; M Sahai
Journal:  Basic Res Cardiol       Date:  1992 Nov-Dec       Impact factor: 17.165

2.  Cardiac toxicity and antitumor activity of 4'-deoxy-4'-iodo-doxorubicinol.

Authors:  R Danesi; A Marchetti; N Bernardini; R V La Rocca; G Bevilacqua; M Del Tacca
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Doxorubicin cardiotoxicity is associated with alterations of plasma levels of atrial natriuretic factor.

Authors:  N Bernardini; C Agen; S Favilla; R Danesi; M Del Tacca
Journal:  J Endocrinol Invest       Date:  1992-02       Impact factor: 4.256

4.  Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4'-amino-3'-hydroxy-doxorubicin.

Authors:  R Danesi; N Bernardini; C Agen; M Costa; L Zaccaro; D Pieracci; G Malvaldi; M Del Tacca
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

6.  Effects of adriamycin and candesartan on the collagen and elastin of the aorta in rats.

Authors:  Jae-Sun Uhm; Woo-Baek Chung; Jung-Sook Yoon; Yong-Seog Oh; Ho-Joong Youn
Journal:  Clin Hypertens       Date:  2014-09-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.